Form 4: BIO-TECHNE CFO's Routine Equity Vesting & Tax Sale
Insider Transaction Report
BIO-TECHNE Corp's CFO, James Hippel, reported a routine acquisition of common stock from RSU vesting and a subsequent disposition of shares for tax withholding purposes.
Summary
- James Hippel, Chief Financial Officer of BIO-TECHNE Corp (TECH), reported transactions on August 15, 2025.
- Acquired 4,010 shares of common stock through the vesting of Restricted Stock Units (RSUs) at a price of $0.
- Disposed of 1,926 shares of common stock at a price of $53.6 per share to cover tax withholding obligations related to the RSU vesting.
- Following these transactions, James Hippel beneficially owns 129,883 shares of BIO-TECHNE common stock directly.
- The filing also details various derivative securities held, including 592,438 shares underlying stock options with exercise prices ranging from $47.6 to $120.46 and expiration dates up to August 15, 2035.
- Additionally, 137,831 Restricted Stock Units (RSUs) and Performance Restricted Stock Units are held, with various vesting schedules extending to August 15, 2028, contingent on time and performance goals.
Sentiment
Score: 5
Explanation: The filing reports a routine insider transaction involving the vesting of equity awards and the subsequent sale of shares to cover tax obligations. This is a common and expected event for executives and does not indicate a significant positive or negative sentiment regarding the company's performance or outlook.
Positives
- The acquisition of 4,010 shares of common stock indicates the vesting of equity compensation, which is a positive for the executive's personal stake in the company.
- The continued holding of a substantial number of common shares (129,883) and significant derivative securities (592,438 stock options, 137,831 RSUs) demonstrates ongoing alignment of management's interests with shareholders.
Negatives
- The disposition of 1,926 shares, while for tax purposes, represents a reduction in direct common stock holdings.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Minimal direct impact as this is a routine compensation-related transaction. It demonstrates the ongoing alignment of executive interests with company performance through equity holdings.
- Employees: No direct impact mentioned.
- Customers: No direct impact mentioned.
- Suppliers: No direct impact mentioned.
- Creditors: No direct impact mentioned.
Next Steps
- Future vesting of various stock options and Restricted Stock Units on specified dates, contingent on time and/or performance goals, as detailed in the filing's footnotes.
Key Dates
| Date | Description |
|---|---|
| 08/15/2023 | Vesting date for a portion of stock options (11,305 shares). |
| 08/15/2024 | Vesting date for a portion of stock options (11,305 shares and 11,481 shares). |
| 08/15/2025 | Transaction date for RSU vesting and tax-related disposition; also a vesting date for stock options (11,305 shares, 11,481 shares, 8,104 shares) and Restricted Stock Units (4,010 units). |
| 08/19/2025 | Signature date of the Form 4 filing. |
| 11/01/2025 | Vesting date for 13,159 Restricted Stock Units and 11,545 Restricted Stock Units. |
| 08/07/2026 | Expiration date for 186,068 stock options with an exercise price of $47.6. |
| 08/15/2026 | Vesting date for a portion of stock options (11,305 shares, 11,480 shares, 8,104 shares, 12,544 shares) and Restricted Stock Units (4,010 units, 4,903 units); also a performance goal achievement date for 37,314 Performance Stock Options and 13,865 Performance Restricted Stock Units. |
| 11/01/2026 | Vesting date for 11,545 Restricted Stock Units. |
| 08/05/2027 | Expiration date for 167,328 stock options with an exercise price of $66.97. |
| 08/15/2027 | Vesting date for a portion of stock options (11,481 shares, 8,104 shares, 12,544 shares) and Restricted Stock Units (4,011 units, 4,903 units); also a performance goal achievement date for 24,062 Performance Restricted Stock Units. |
| 11/01/2027 | Vesting date for 11,544 Restricted Stock Units. |
| 08/06/2028 | Expiration date for 40,536 stock options with an exercise price of $120.46. |
| 08/15/2028 | Vesting date for a portion of stock options (8,105 shares, 12,544 shares) and Restricted Stock Units (4,904 units); also a performance goal achievement date for 29,420 Performance Restricted Stock Units. |
| 08/15/2029 | Expiration date for 45,220 stock options with an exercise price of $94.52. |
| 08/15/2030 | Expiration date for 37,314 Performance Stock Options and 45,923 Stock Options with an exercise price of $84.61. |
| 08/15/2034 | Expiration date for 32,417 stock options with an exercise price of $74.91. |
| 08/15/2035 | Expiration date for 37,632 stock options with an exercise price of $53.6. |
Keywords
BIO-TECHNE, TECH, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, CFO, Equity Compensation, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.